戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ized that these lymphocytes would respond to forodesine.
2 LL lymphocytes with 10 or 20 microM dGuo and forodesine (2 microM) resulted in accumulation of higher
3 h progressive disease were eligible for oral forodesine (200 mg/d) for up to 24 weeks.
4 were treated with an intravenous infusion of forodesine (40 mg/m2) on day 1; treatment continued on d
5                         Median peak level of forodesine (5.4 microM) was achieved at the end of infus
6 e-based synthesis of immucillin-H (BCX-1777, forodesine), a transition-state analog of PNP.
7                                              Forodesine, a potent inhibitor of PNP, was designed base
8                                              Forodesine, a purine nucleoside phosphorylase inhibitor,
9 onversely, MSC viability was not affected by forodesine and dGuo.
10 rom 12 patients with CLL were incubated with forodesine and dGuo.
11 ical mechanism for MSC-derived resistance to forodesine and emphasizes the need to move toward combin
12 d on these data, a phase 2 clinical trial of forodesine has been initiated for CLL patients.
13                                              Forodesine has biologic activity in CLL; pharmacodynamic
14               Initial clinical data indicate forodesine has significant activity on circulating CLL c
15 odynamic effectiveness of the PNP inhibitor, forodesine; however, regrowth of leukemia cells in the b
16 fere with the purine metabolic pathway (e.g. forodesine), immunomodulatory agents, proapoptotic small
17                  A phase 1 clinical trial of forodesine in T-cell malignancies demonstrated significa
18 al studies provided the rationale for use of forodesine in T-cell malignancies.
19            Previous studies established that forodesine in the presence of deoxyguanosine (dGuo) inhi
20          We demonstrate that spontaneous and forodesine-induced apoptosis of CLL cells was significan
21  MSC-induced biochemical changes antagonized forodesine-induced CLL cell apoptosis.
22 the impact of marrow stromal cells (MSCs) on forodesine-induced response in CLL lymphocytes.
23            Also, MSCs rescued CLL cells from forodesine-induced RNA- and protein-synthesis inhibition
24                                              Forodesine is a new and potent purine nucleoside phospho
25                                              Forodesine-promoted dGuo triphosphate (dGTP) accumulatio
26                        Steady-state level of forodesine ranged from 200 to 1300 nM and did not reach
27 /m2) on day 1; treatment continued on day 2; forodesine was administered every 12 hours for an additi

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。